Evgen Pharma PLC Upcoming Investor Presentations
May 14 2018 - 2:00AM
RNS Non-Regulatory
TIDMEVG
Evgen Pharma PLC
14 May 2018
For immediate release 14 May 2018
RNS REACH
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Upcoming Investor Presentations
Evgen Pharma (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, is pleased to announce that Dr Stephen Franklin, the
Company's CEO, will present at a series of upcoming investor
evenings.
The presentation will focus on the Phase II trials of SFX-01,
the Company's lead product, in the treatment of breast cancer and
subarachnoid haemorrhage, a type of stroke.
Investors and shareholders wishing to register for the investor
presentations may do so through the links provided below.
16 May 2018 - ShareSoc Growth Company Seminar, London
Time: The presentation will start at 5.30pm followed by a buffet
and refreshments.
Location: Link Asset Services, 65 Gresham Street, London, EC2V
7NQ.
Link to register:
https://www.sharesoc.org/events/sharesoc-growth-company-seminar-in-london-16-may-2018/
17 May 2018 - Proactive Investors Healthcare, London
Time: The presentation will start at 6.00pm followed by drinks
and canapés.
Location: Chesterfield Mayfair Hotel, 35 Charles Street, London,
W1J 5EB.
Link to register:
http://www.proactiveinvestors.co.uk/register/event_details/142
19 June 2018 - ShareSoc Growth Company Seminar, Manchester
Time: The presentation will start at 5.30pm followed by a buffet
and refreshments.
Location: Kuits Solicitors, 7(th) Floor, Blackfriars House,
Manchester, M3 2JA.
Link to register:
https://www.sharesoc.org/events/sharesoc-growth-company-seminar-in-manchester-19-june-2018/
A copy of the latest investor presentation will be available
from 12pm on 15 May 2018 at:
http://evgen.com/investors/shareholder-information/
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466 5000
Dr Stephen Franklin, CEO
Richard Moulson, CFO
www.evgen.com
Buchanan
Mark Court, Sophie Wills, Stephanie Watson +44 (0) 20 7466 5000
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
focussed on the development of a new class of pharmaceutical;
sulforaphane-based compounds for application in oncology and
neurology markets. Lead product, SFX-01, is in two Phase II trials,
utilising two separate mechanistic targets, with expected read-outs
around the end of 2018.
Evgen Pharma commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFMGMKDFMGRZM
(END) Dow Jones Newswires
May 14, 2018 02:00 ET (06:00 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024